Boersma, L., Barr, C., Burke, M., Leon, A., Theuns, D., Herre, J., . . . Gold, M. (2017). Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Boersma, LV, Barr, CS, Burke, MC, Leon, AR, Theuns, D, Herre, JM, Weiss, R, Kremers, MS, Neuzil, P, Husby, MP, Carter, N, Stivland, TM & Gold, MR 2017, 'Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication', Heart Rhythm, vol. 14, no. 3, pp. 367-375. https://doi.org/10.1016/j.hrthm.2016.11.025. https://doi.org/10.1016/j.hrthm.2016.11.025
Παραπομπή σε μορφή Chicago (17η εκδ.)Boersma, LV, et al. "Performance of the Subcutaneous Implantable Cardioverter-defibrillator in Patients with a Primary Prevention Indication with and Without a Reduced Ejection Fraction Versus Patients with a Secondary Prevention Indication." Boersma, LV, Barr, CS, Burke, MC, Leon, AR, Theuns, D, Herre, JM, Weiss, R, Kremers, MS, Neuzil, P, Husby, MP, Carter, N, Stivland, TM & Gold, MR 2017, 'Performance of the Subcutaneous Implantable Cardioverter-defibrillator in Patients with a Primary Prevention Indication with and Without a Reduced Ejection Fraction Versus Patients with a Secondary Prevention Indication', Heart Rhythm, Vol. 14, No. 3, Pp. 367-375. Https://doi.org/10.1016/j.hrthm.2016.11.025 2017. https://doi.org/10.1016/j.hrthm.2016.11.025.
Παραπομπή σε μορφή MLA (9th εκδ.)Boersma, LV, et al. "Performance of the Subcutaneous Implantable Cardioverter-defibrillator in Patients with a Primary Prevention Indication with and Without a Reduced Ejection Fraction Versus Patients with a Secondary Prevention Indication." Boersma, LV, Barr, CS, Burke, MC, Leon, AR, Theuns, D, Herre, JM, Weiss, R, Kremers, MS, Neuzil, P, Husby, MP, Carter, N, Stivland, TM & Gold, MR 2017, 'Performance of the Subcutaneous Implantable Cardioverter-defibrillator in Patients with a Primary Prevention Indication with and Without a Reduced Ejection Fraction Versus Patients with a Secondary Prevention Indication', Heart Rhythm, Vol. 14, No. 3, Pp. 367-375. Https://doi.org/10.1016/j.hrthm.2016.11.025, 2017, https://doi.org/10.1016/j.hrthm.2016.11.025.